SynchroMed II Drug Infusion System

Catheter Access Port Kits for use with Medtronic Implantable Infusion Pumps instructions for use.

This reference manual contains information specifically regarding indications, drug stability and emergency procedures for the SynchroMed and IsoMed Infusion Systems.

This implant manual includes the instructions for use for the Indura^® 1P model 8709SC.

This implant manual includes the instructions for use for the Intrathecal Catheter and Sutureless Connector model 8731SC.

This manual presents information for users of the N'Vision Clinician Programmer model 8840 including an overview and description, as well as the use, maintenance, troubleshooting, and specifications of the Programmer.

This document contains prescribing information related to the myPTM programmer model 8835.

This is the instructions for use for the myPTM programmer model 8835 used with the SynchroMed II infusion system.

Intructions for use for the Sutureless Pump Connector Revision Kit for model 8709 and model 8709SC intrathecal catheters.

This is the instructions for use for the SynchroMed II Programmable drug infusion system model 8637.

Information for prescribers for the SynchroMed II Programmable Infusion System model 8637.

This is the user manual for the myPTM programmer model 8835.

This is the user manual for the Personal Therapy Manager (PTM) model 8832.

This is the user manual for the SynchroMed II Programmable Infusion System model 8637.

Whenever there is a change in drug concentration or solution, the remaining old drug in the pump tubing and catheter must be accounted for to prevent under- or overdosing the patient while the old drug concentration is being cleared from the fluid pathway. This reference card outlines how to calculate a bridge bolus.

The existing implanted pump internal pump tubing, reservoir and any unrevised catheter segment are full of drug following a catheter revision. All unrevised spinal catheter segments must be aspirated. A priming bolus is programmed to advance the drug to the tip of the catheter. Before executing a priming bolus it is important to know the location of drug.

The existing implanted pump internal pump tubing and reservoir are full of drug following a catheter replacement. A priming bolus is programmed to advance drug to the tip of the catheter. Before executing a priming bolus it is important to know the location of drug.

This card provides information on the identification of symptoms and suggestions for treatment for morphine Intrathecal/epidural overdose.

This guide describes a low-complication catheter implant procedure for the 8709SC and 8731SC catheters.

This guide provides an overview of operating N'Vision software. Includes a description of programming parameters and calculations.

In view of the increase risk of mortality in the period immediately after implant, revision, and refill of intrathecal pumps and catheters, it is important to emphasize the procedures that can minimize risk in this period.

Mortality rates associated with intrathecal therapy in the 3-day post-implant period and at other selected intervals were measured, and mechanisms of any deaths observed after initiation of intrathecal opioid therapy in patients with non-cancer pain were explored.

This guide provides an overview of how to operate the N'Vision Clinician Programmer.

This card offers a quick overview of how to use the myPTM programmer model 8835.

This card offers a quick overview of how to use the Personal Therapy Manager model 8832.

The internal pump tubing and reservoir are filled with water during the manufacturing process. Before the drug is injected into the reservoir, the water is aspirated. At implant, a priming bolus is programmed to advance drug to the tip of the catheter. Before executing a priming bolus it is important to know the location of drug or other fluid in the system.

This is a supplement to the clinical reference guide and has detailed information about the sutureless connector.

Medtronic has confirmed through engineering analyses that the use of indicated and nonindicated drug formulations can result in collection of CSF protein in the catheter lumen, distal end. Although this may occur with any drug, nonindicated drug formulations can result in significantly increased collections of material in the catheter lumen resulting in complete occlusion of the catheter.

Medtronic has confirmed through returned product analysis that the use of nonindicated drug formulations can compromise the performance of the SynchroMed II and SynchroMed EL infusion systems. This paper discusses the mechanism by which nonindicated drug formations can cause corrosion to the pumps internal components, resulting in permanent motor stalls and therapy cessation.

Information for prescribers for the SynchroMed II Programmable Infusion System model 8637.

This guide provides an overview of operating the N'Vision software for the SynchroMed II Infusion System, myPTM personal therapy manager and the patient activation feature.

SynchroMed II programming guide for software application card model 8870 software version B.

This guide provides additional tips and pointers for programming SynchroMed II and SynchroMed EL infusion systems.

This reference guide offers in-depth information on programming the SynchroMed II programmable pump and intrathecal morphine for pain management.

This guide provides in-depth information on the personal therapy manager (myPTM) and the patient activation software option on the N'Vision Programmer.

This module of the Clinical Reference Guide offers in-depth information on programming the SynchroMed II programmable pump.

This module of the Clinical Reference Guide offers in-depth information on implanting and replacing a SynchroMed II implantable drug pump.

This manual offers in-depth information on the various components used when implanting or replacing a SynchroMed II implantable drug pump.

This module of the Clinical Reference Guide offers in-depth information on therapy maintenance, patient education, complications management, and more.